文献速递白血病

T细胞免疫对儿童急性淋巴细胞白血病化疗反应的影响

Impact of T-cell immunity on chemotherapy response in childhood acute lymphoblastic leukemia.
PubMed 文献 · Blood · 2022-01-01

研究利用Arf-/-BCR-ABL1 B细胞急性淋巴细胞白血病小鼠模型,发现宿主T细胞缺失会大幅增加达沙替尼或细胞毒性化疗后的白血病复发;T细胞免疫对抑制耐药白血病扩增至关重要。对102例化疗期间儿童ALL患者外周血免疫细胞组成的评估显示,T细胞丰度与治疗结局显著相关。

要点

  • 小鼠模型中宿主T细胞缺失大幅增加达沙替尼或细胞毒性化疗后的白血病复发。
  • T细胞免疫对抑制耐药白血病扩增至关重要,尽管ABL1突变在达沙替尼治疗早期即出现。
  • 102例儿童ALL化疗期间外周血T细胞丰度与治疗结局显著相关。

核心结论

  • T细胞免疫在维持急性淋巴细胞白血病长期缓解中起关键作用,宿主免疫与耐药性的相互作用可用于改善ALL化疗结局。

研究设计与样本

  • 研究采用Arf-/-BCR-ABL1 B细胞急性淋巴细胞白血病小鼠模型,系统评估T细胞免疫对Ph+ ALL治疗结局的影响。
  • 对102例化疗期间儿童ALL患者的外周血免疫细胞组成进行了评估。

主要发现

  • 小鼠模型中宿主T细胞缺失大幅增加达沙替尼或细胞毒性化疗后的白血病复发。
  • ABL1突变在达沙替尼治疗早期于免疫正常和免疫缺陷宿主中均出现,但T细胞免疫对抑制耐药白血病扩增至关重要。
  • 治疗期间T细胞转录组分析提示1型免疫相关细胞因子信号激活与小鼠长期白血病缓解相关。
  • 干扰素γ和白介素12在体内直接调节达沙替尼抗白血病疗效。
  • 102例儿童ALL患者化疗期间外周血T细胞丰度与治疗结局显著相关。

临床怎么用

  • 原文未据此给出临床推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Although acute lymphoblastic leukemia (ALL) is highly responsive to chemotherapy, it is unknown how or which host immune factors influence the long-term remission of this cancer. To this end, we systematically evaluated the effects of T-cell immunity on Ph+ ALL therapy outcomes. Using a murine Arf-/-BCR-ABL1 B-cell ALL model, we showed that loss of T cells in the host drastically increased leukemia relapse after dasatinib or cytotoxic chemotherapy. Although ABL1 mutations emerged early during dasatinib treatment in both immunocompetent and immunocompromised hosts, T-cell immunity was essential for suppressing the outgrowth of drug-resistant leukemia. Bulk and single-cell transcriptome profiling of T cells during therapy pointed to the activation of type 1 immunity-related cytokine signaling being linked to long-term leukemia remission in mice. Consistent with these observations, interferon γ and interleukin 12 directly modulated dasatinib antileukemia efficacy in vivo. Finally, we evaluated peripheral blood immune cell composition in 102 children with ALL during chemotherapy and observed a significant association of T-cell abundance with treatment outcomes. Together, these results suggest that T-cell immunity plays pivotal roles in maintaining long-term remission of ALL, highlighting that the interplay between host immunity and drug resistance can be harnessed to improve ALL chemotherapy outcomes.

来源:Blood,查看原文。版权归原作者所有。

引用

  1. Li Y, Yang X, Sun Y, et al. Impact of T-cell immunity on chemotherapy response in childhood acute lymphoblastic leukemia. Blood. 2022. PMID: 35675514. doi:10.1182/blood.2021014495

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。